U.S. Health Care REITs Stock News

Wondering if Prologis could be a smart buy or if its recent price reflects real value? You are not alone, as plenty of investors want to know if today's stock price is justified or simply riding the wave of market momentum. Prologis shares are up 17.8% since the start of the year and have gained 12.3% over the past 12 months. The past week, however, saw a slight dip of 2.2%. News around Prologis has centered on the ongoing strength of e-commerce and supply chain investments. Both of these...

In recent days, Wells Fargo downgraded Cooper Companies to Equal Weight from Overweight, highlighting concerns about a slowdown in its core contact lens markets. This shift in analyst outlook underscores emerging uncertainty around consumer demand and growth momentum in key segments for the company. We'll now examine how signs of slowing market demand may affect Cooper Companies' previously established investment narrative. Explore 26 top quantum computing companies leading the revolution in...

Earlier this month, Cytek Biosciences reported third-quarter 2025 earnings, showing revenue of US$52.29 million and a net loss of US$5.48 million compared to net income in the prior year, and reaffirmed its full-year revenue guidance of US$196 million to US$205 million. This combination of improved quarterly revenue but a swing to quarterly and year-to-date losses provided investors with contrasting signals about Cytek’s ongoing financial health and outlook. We’ll review how the...

Inter & Co (NasdaqGS:INTR) has recently shown some interesting movement, especially when viewed over the past month. Investors are paying attention as the bank’s shares have gained 4% during that period. With strong annual revenue and net income growth, the company appears positioned for further scrutiny in the financial sector. See our latest analysis for Inter & Co. Inter & Co’s share price momentum shows no signs of slowing, with a 14% gain over the last three months helping propel its...

Earlier this month, QuidelOrtho Corporation announced FDA clearance for its VITROS High Sensitivity Troponin assay, reported a quarterly net loss of US$733 million on sales of US$699.9 million, and issued 2025 guidance projecting total revenues between US$2.68 billion and US$2.74 billion. Alongside these financial disclosures, the company highlighted over US$140 million in recent cost savings and a product pipeline expansion into cardiac diagnostics, signaling ongoing efforts to improve...

Earlier this month, Hamilton Insurance Group reported strong third quarter 2025 earnings with revenue of US$667.65 million and net income of US$136.2 million, alongside the completion of a 5.35% share repurchase totaling US$113.82 million since August 2024. The company's decision to expand its buyback authorization to US$300 million shortly after its earnings release highlights management's confidence and commitment to returning value to shareholders. We’ll explore how Hamilton’s increased...

Wondering if Enphase Energy is trading at an attractive price or if there’s still risk of a value trap? You’re not alone. With so much market noise, now is the perfect time to dig into what the numbers really say. After sliding 23.6% in the last month and 59.8% so far this year, Enphase’s recent price moves highlight how quickly investor sentiment has shifted, raising questions about both risk and recovery potential. Media coverage has focused on the broader solar and semiconductor sector...

C.H. Robinson Worldwide (CHRW) just bumped up its quarterly cash dividend by 1.6%, continuing a 25-year streak of annual increases. This move, along with steady earnings despite a challenging freight market, has caught investors’ attention. See our latest analysis for C.H. Robinson Worldwide. Momentum has clearly returned for C.H. Robinson Worldwide, with its stock climbing 19.4% over the past month and boasting a 48.7% share price return so far this year. The recent dividend hike and solid...

Wondering if Tyson Foods could be a value play that's flying under the radar? You are not alone, as many investors keep an eye on staples like Tyson to spot potential bargains. The stock has seen a bit of a rebound lately, climbing 2.5% over the past week and 2.2% over the last month. It's still down 13.2% over the past year. Recent headlines have centered around industry-wide shifts in protein demand and supply chain adaptation, which have fueled speculation about Tyson's market...

Strategic Education recently reported third quarter results, highlighted by a year-over-year rise in sales to US$319.95 million, stable net income, a regular US$0.60 per share dividend declaration, and the completion of an additional share buyback tranche totaling 428,837 shares for US$34.29 million. With over half of its buyback program now completed and continued shareholder payouts, the company is reinforcing a focus on capital returns even as operational performance remains steady. We’ll...

AIRO Group Holdings announced its third quarter 2025 results, reporting US$6.28 million in sales and a net loss of US$7.96 million, both significantly lower than the prior year's figures for the same period. The company's ability to substantially reduce losses despite experiencing lower sales highlights a shift in operational efficiency that may alter future expectations. We will explore how AIRO Group Holdings' progress in narrowing its net loss shapes its current investment narrative. AI...

Inhibrx Biosciences (INBX) shared that its Phase 2 trial for ozekibart in chondrosarcoma achieved its primary endpoint, showing a clear improvement in progression-free survival. The company now plans to move forward and submit a biologics license application to the FDA next year, an important step that reflects confidence in its trial results and future prospects. See our latest analysis for Inhibrx Biosciences. Inhibrx Biosciences’ journey over the past year reflects how powerful clinical...

Autolus Therapeutics (AUTL) just released its latest quarterly earnings and is drawing increased investor attention thanks to several key developments. The company continues to expand commercial access for Obe-cel, reports strong manufacturing results, and anticipates new data at the upcoming ASH conference. See our latest analysis for Autolus Therapeutics. Autolus Therapeutics has seen a burst of activity lately, from broadening commercial access and updating its leadership team to advancing...

UWM Holdings recently reported its third quarter results, narrowed its net loss year-over-year, provided fourth quarter 2025 production guidance in the US$43 billion to US$50 billion range, and reaffirmed its regular US$0.10 per share dividend, continuing a 20-quarter streak. This combination of forward guidance, improved quarterly performance, and a consistent dividend signal underscores management’s focus on operational stability amid ongoing market headwinds. We'll examine how the newly...

General Electric (GE) shares have edged higher recently, building on a strong performance over the past quarter. Investor interest is being driven by the company’s steady results and overall resilience in the industrial sector. See our latest analysis for General Electric. General Electric’s share price has shown impressive momentum, climbing over 13% in the last quarter and delivering a year-to-date gain of over 80%. With a one-year total shareholder return of 73% and an exceptional...

Quest Diagnostics (DGX) has experienced some movement in its stock price recently, gaining 4% over the past week after a slight dip last month. Investors are watching its performance closely as market sentiment shifts. See our latest analysis for Quest Diagnostics. After shaking off a dip last month, Quest Diagnostics has regained positive momentum, with its share price up nearly 24% year-to-date and a solid 18.7% total shareholder return over the past year. This steady climb suggests...

Pfizer’s move to sell its remaining stake in BioNTech (NasdaqGS:BNTX) through an overnight block trade has grabbed investor attention. The stake sale signals Pfizer’s exit as an equity holder, even as the companies continue collaborating on vaccines. See our latest analysis for BioNTech. The Pfizer stake sale made headlines, but BioNTech’s year has been marked by more than just this event. The company recently boosted its revenue guidance after strong collaboration sales and has focused fresh...

Disc Medicine (IRON) is making waves with two major updates. The company has launched a Phase 1b trial for its investigational therapy in sickle cell disease, and the FDA has granted priority review to its new drug application for bitopertin. See our latest analysis for Disc Medicine. Disc Medicine’s clinical and regulatory momentum appears to be fueling strong investor interest, with the stock delivering a robust 51.3% total shareholder return over the past year and a 50% share price return...

In recent days, J.B. Hunt Transport Services underscored growing concerns over a trucking capacity crisis driven by regulatory changes affecting commercial driver’s licenses and an 18% year-over-year decline in freight volumes. This heightened capacity pressure adds further operational challenges to an industry already contending with supply-chain disruption, elevated interest rates, and a severe shortage of truck drivers. We’ll review how the anticipated reduction in qualified drivers and...

CorMedix (CRMD) just released quarterly results showing a dramatic swing to profitability and sharp revenue growth compared to last year. The company also shared a confident revenue outlook for the next quarter. Investors are paying close attention. See our latest analysis for CorMedix. After swinging to profitability and increasing revenue, CorMedix’s stock has picked up short-term momentum, with a 1-month share price return of nearly 6 percent and a robust year-to-date gain of 36.7 percent...

In its latest quarterly report, Five9, Inc. announced third quarter 2025 revenues of US$285.83 million and net income of US$17.97 million, marking a shift to profitability compared to last year's net loss for the same period; the company also rolled out a US$150 million share repurchase program and issued updated guidance for both the fourth quarter and full year 2025. Five9's move into profitability, alongside the initiation of a significant buyback program and raised financial guidance,...

Legence (LGN) shares have moved higher recently, catching investors’ attention after the company reported a strong annual net income improvement and steady revenue growth. The stock is up more than 20% over the past month. See our latest analysis for Legence. Legence’s 1-month share price return of 20.2% is grabbing attention, especially after its annual profit surge. Momentum appears to be building as confidence returns and investors increasingly factor in the company’s growth story. With...

Valvoline (VVV) has caught some attention recently as its shares tracked lower over the past month, declining around 11%. Investors might be curious about what is driving the movement and whether it reflects broader trends for the company. See our latest analysis for Valvoline. It’s been a rough patch for Valvoline, with the share price down 10.7% over the past month and 20% over the last quarter. This drop continues a longer trend, as the 1-year total shareholder return now sits at -25.7%...

NOV (NOV) has entered into a Memorandum of Understanding with Soiltech to team up on selected global projects in drilling waste management. The two companies will work together to develop customized solutions for clients by leveraging their respective technologies. This collaboration has raised investor interest in NOV’s potential for broader service offerings and market expansion. See our latest analysis for NOV. Momentum appears to be building for NOV, with a 30-day share price return of...